Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue

Amgen and Vertex Pharmaceuticals present contrasting investment profiles: Amgen generates significantly larger quarterly revenues ($8.1B-$10.1B) with moderate fluctuations and expects ~3% growth in 2026, while Vertex shows steady, gradual revenue growth ($2.8B-$3.3B) driven by its cystic fibrosis focus and the promising Alyftrek treatment. Vertex's expansion into autoimmune diseases with Povetacicept could reach $4-7B in peak annual sales, while Amgen's scale and six $1B+ drug franchises provide acquisition capacity despite slower growth.